Skip to main content
SpringerLink
Log in

Epidemiology of Alcohol and Drug Use

  • Chapter
  • First Online:
Drug Abuse and Addiction in Medical Illness

  • 5103 Accesses

Abstract

This chapter describes trends in the prevalence and patterns of alcohol and illicit drug use. While methodological differences, imprecise estimates and lack of data preclude firm conclusions on the global situation and trends in substance use, the available data suggest that alcohol and illicit drug consumption varies widely between societies. Per capita alcohol consumption is highest in the European Union and lowest in the South-East Asian and Eastern Mediterranean regions. There is a general long-term trend towards harmonisation of alcohol consumption, with decreasing levels in regions with traditionally high levels and increasing levels in regions with low levels. Trend data from surveys showed an increase in heavy episodic drinking among pupils in many European countries in the past decade, especially among girls.

Prevalence rates of illicit drug use are generally lower in the European Union compared to the USA, Canada and Australia, for which most research data are available. However, there are large variations between EU countries. Cannabis is worldwide the most frequently used illicit drug. Prevalence rates among young people tend to stabilise or decline in the past years, after a general increasing trend in the 1990s. Annual cocaine prevalence is higher among the general population of the USA and Canada compared to Australia and the EU, while annual prevalence of ecstasy and amphetamine use is highest in Australia. Within Europe, cocaine generally dominates the stimulant markets in the Western and Southern regions, albeit restricted to a few large countries. Amphetamines are the main stimulants in North, Central and Eastern Europe. Injecting drug use increases the risk of transmission of blood-born infectious diseases, like HIV and hepatitis B and C. China, the USA and Russia have the largest numbers of drug injectors. In terms of (midpoint) prevalence, highest rates are found in Azerbaijan and lowest in Cambodia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    For the EU, recent and more comparable figures are available from the Eurobarometer survey in 2006 [12]. This survey showed a last year prevalence of abstinence 25% (males 16%, females 32%) in the population of 15 years and above of the EU-25, with highest rates reported in Italy (40%), Hungary (38%), Portugal (37%) and Malta (35%), and lowest rates of abstinence in Denmark [13] and the Netherlands (10%). See also paragraph on binge drinking. Note, however, that precision of estimates owing to comparability of methods is partly offset by the fairly small sample (roughly 1,000 respondents per country, with some exceptions).

References

  1. Leung KS, Cottler LB. Ecstasy and other club drugs: a review of recent epidemiologic studies. Curr Opin Psychiatry. 2008;21:234–41.

    Article  PubMed  Google Scholar 

  2. EMCDDA. Annual report: the state of the drugs problem in Europe. Lisbon: EMCDDA; 2009. p. 2009.

    Google Scholar 

  3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Selected Issue 2009: Polydrug use: patterns and responses. Luxembourg: Office for Official Publications of the European Communities; 2009.

    Google Scholar 

  4. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA 2002: Selected issue: polydrug use. Lisbon: EMCDDA; 2002.

    Google Scholar 

  5. World Health Organization. Global status report on alcohol 2004. Geneva: WHO; 2004.

    Google Scholar 

  6. Anderson P, Baumberg B. Alcohol in Europe: a public health perspective: a report for the European Commission. London: Institute of Alcohol Studies; 2006.

    Google Scholar 

  7. Rehm J, Room R, Van den Brink W, Kraus L. Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol. 2005;15(4):389–97.

    Article  PubMed  CAS  Google Scholar 

  8. Bobak M, Room R, Pikhart H, Kubinova R, Malyutina S, Pajak A, et al. Contribution of drinking patterns to differences in rates of alcohol related problems between three urban populations. J Epidemiol Community Health. 2004;58(3):238–42.

    Article  PubMed  CAS  Google Scholar 

  9. Gmel G, Room R, Kuendig H, Kuntsche S. Detrimental drinking patterns: empirical validation of the pattern values score of the Global Burden of Disease 2000 study in 13 countries. J Subst Use. 2007;12:337–58.

    Article  Google Scholar 

  10. Rehm J, Rehn N, Room R, Monteiro M, Gmel G, Jernigan D, et al. The global distribution of average volume of alcohol consumption and patterns of drinking. Eur Addict Res. 2003;9(4):147–56.

    Article  PubMed  Google Scholar 

  11. Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn N, et al. Alcohol use. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks global and regional burden of disease attributable to selected major risk factors. Geneva: WHO; 2004. p. 959–1108.

    Google Scholar 

  12. European Commission. Attitudes towards alcohol: special Eurobarometer 272. Brussel: European Commission; 2007.

    Google Scholar 

  13. Comminity Epidemiology Work Group. Epidemiologic Trends in Drug Abuse: Proceedings of the Community Epidemiology Work Group: Highlights and Executive Summary. Bethesda, MD: National Institute of Drug Abuse; 2008.

    Google Scholar 

  14. Neumark YD, Lopez-Quintero C, Grinshpoon A, Levinson D. Alcohol drinking patterns and prevalence of alcohol-abuse and dependence in the Israel National Health Survey. Isr J Psychiatry Relat Sci. 2007;44(2):126–35.

    PubMed  Google Scholar 

  15. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-­analysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224):1523–8.

    Article  PubMed  CAS  Google Scholar 

  16. Fillmore KM, Kerr WC, Stockwell T, Chikritzhs T, Bostrom A. Moderate alcohol use and reduced mortality risk: systematic error in prospective studies. Addict Res Theory. 2006;14:101–32.

    Article  Google Scholar 

  17. Lauer MS, Sorlie P. Alcohol, cardiovascular disease, and cancer: treat with caution. J Natl Cancer Inst. 2009;101(5):282–3.

    Article  PubMed  Google Scholar 

  18. Greenfield TK. Individual risk of alcohol-related disease and problems. In: Heather N, Peters T, Stockwell T, editors. International handbook of alcohol dependence and problems. New York: Wiley; 2001. p. 413–37.

    Google Scholar 

  19. Sundell L, Salomaa V, Vartiainen E, Poikolainen K, Laatikainen T. Increased stroke risk is related to a binge-drinking habit. Stroke. 2008;39(12):3179–84.

    Article  PubMed  Google Scholar 

  20. Deutsche Hauptstelle für Suchtfragen e.V.(DHS). Binge drinking and Europe. Hamm: DHS; 2008.

    Google Scholar 

  21. Naimi TS, Brewer RD, Mokdad A, Denny C, Serdula MK, Marks JS. Binge drinking among US adults. JAMA. 2003;289(1):70–5.

    Article  PubMed  Google Scholar 

  22. AIHW. National drug strategy household survey: detailed findings. Canberra: AIHW; 2007. p. 2008.

    Google Scholar 

  23. Clark DB, Thatcher DL, Tapert SF. Alcohol, psychological dysregulation, and adolescent brain development. Alcohol Clin Exp Res. 2008;32:375–85.

    Article  PubMed  Google Scholar 

  24. Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et al. The 2007 ESPAD report: substance use among students in 35 European countries. Stockholm: CAN; 2009.

    Google Scholar 

  25. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national results on adolescent drug use: overview of key findings, 2008. Bethesda, MD: National Institute on Drug Abuse; 2009.

    Google Scholar 

  26. Hasin D. Classification of alcohol use disorders. Alcohol Res Health. 2003;27(1):5–17.

    PubMed  Google Scholar 

  27. De Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J Psychiatry. 2002;159(4):620–9.

    Article  PubMed  Google Scholar 

  28. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830–42.

    Article  PubMed  Google Scholar 

  29. Grant BF. Toward an alcohol treatment model: a comparison of treated and untreated respondents with DSM-IV alcohol use disorders in the general population. Alcohol Clin Exp Res. 1996;20(2):372–8.

    Article  PubMed  CAS  Google Scholar 

  30. Grant BF, Compton WM, Crowley TJ, Hasin DS, Helzer JE, Li TK, et al. Errors in assessing DSM-IV substance use disorders. Arch Gen Psychiatry. 2007;64:379–80.

    Article  PubMed  Google Scholar 

  31. Cottler LB. Drug use disorders in the National Comorbidity Survey: have we come a long way? Arch Gen Psychiatry. 2007;64:380–1.

    Article  PubMed  Google Scholar 

  32. Kessler RC, Merikangas KR. Drug use disorders in the National Comorbidity Survey: have we come a long way? In reply. Arch Gen Psychiatry. 2007;64:381–2.

    Article  Google Scholar 

  33. Kessler RC, Üstün TB. The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders. New York: Cambridge University Press; 2008.

    Google Scholar 

  34. Oakley Browne MA, Wells JE, Scott KM. Te Rau Hinengaro: the New Zealand Mental Health Survey. Wellington: Ministry of Health; 2006.

    Google Scholar 

  35. Bromet EJ, Gluzman SF, Paniotto VI, Webb CP, Tintle NL, Zakhozha V, et al. Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey. Soc Psychiatry Psychiatr Epidemiol. 2005;40(9):681–90.

    Article  PubMed  Google Scholar 

  36. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21–7.

    PubMed  Google Scholar 

  37. Keyes KM, Grant BF, Hasin DS. Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. Drug Alcohol Depend. 2008;93(1–2):21–9.

    Article  PubMed  Google Scholar 

  38. Dick DM, Bierut LJ. The genetics of alcohol dependence. Curr Psychiatry Rep. 2006;8(2):151–7.

    Article  PubMed  Google Scholar 

  39. Sher KJ, Grekin ER, Williams NA. The development of alcohol use disorders. Annu Rev Clin Psychol. 2005;1:493–523.

    Article  PubMed  Google Scholar 

  40. United Nations Office On Drugs and Crime (UNODC). World Drug Report: 2009. Vienna: UNODC; 2009.

    Google Scholar 

  41. Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): a national survey of Canadians’ use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa: Canadian Centre on Substance Abuse; 2005.

    Google Scholar 

  42. SAMHSA. Results from the 2007 National Survey on Drug Use and Health: National findings. Rockville, MD: Office of Applied Studies; 2008.

    Google Scholar 

  43. Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med. 2008;5(7):e141.

    Article  PubMed  Google Scholar 

  44. Furr-Holden CD, Anthony JC. Epidemiologic differences in drug dependence–a US-UK cross-national comparison. Soc Psychiatry Psychiatr Epidemiol. 2003;38(4):165–72.

    Article  PubMed  Google Scholar 

  45. Kilmer B. Do cannabis possession laws influence cannabis use? In: Spruit IP, editor. Cannabis 2002 report: a joint international effort at the initiative of the Ministers of Public Health of Belgium, France, Germany, The Netherlands, Switserland: technical report of the International Scientific Conference Brussels, Belgium, 25-02-2002. Brussels, Belgium: Ministry of Public Health; 2002. p. 119–42.

    Google Scholar 

  46. Simons-Morton B, Pickett W, Boyce W, Ter Bogt TF, Vollebergh W. Cross-national comparison of adolescent drinking and cannabis use in the United States, Canada, and the Netherlands. Int J Drug Policy. 2010;21(1):64–9.

    Article  PubMed  Google Scholar 

  47. EMCDDA. Annual report 2008: the state of the drugs problem in Europe. Lisbon: EMCDDA; 2008.

    Google Scholar 

  48. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212–3.

    Article  PubMed  Google Scholar 

  49. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99(10):1333–41.

    Article  PubMed  CAS  Google Scholar 

  50. Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction. 2002;97(9):1123–35.

    Article  PubMed  Google Scholar 

  51. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427–33.

    Article  PubMed  Google Scholar 

  52. DeWit DJ, Offord DR, Wong M. Patterns of onset and cessation of drug use over the early part of the life course. Health Educ Behav. 1997;24(6):746–58.

    PubMed  CAS  Google Scholar 

  53. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). A cannabis reader: global issues and local experiences: perspectives on cannabis controversies, treatment and regulation in Europe, vol. 1. Lisbon: EMCDDA; 2008.

    Google Scholar 

  54. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). A cannabis reader: global issues and local experiences: perspectives on cannabis controversies, treatment and regulation in Europe, vol. 2. Lisbon: EMCDDA; 2008.

    Google Scholar 

  55. Australian Institute of Health and Welfare. 2007 National Drug Strategy Household Survey: first results. Canberra: AIHW; 2008.

    Google Scholar 

  56. Currie C, Gabhainn SN, Godeau E, Roberts C, Smith R, Currie D, et al. Inequalities in young people’s health: HBSC international report from the 2005/2006 survey. Copenhagen: World Health Organisation, Europe; 2008.

    Google Scholar 

  57. Chen K, Kandel DB, Davies M. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States. Drug Alcohol Depend. 1997;46(1–2):53–67.

    Article  PubMed  CAS  Google Scholar 

  58. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, et al. Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict. 2006;15(4):297–302.

    Article  PubMed  Google Scholar 

  59. Chen CY, O’Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend. 2005;79(1):11–22.

    Article  PubMed  Google Scholar 

  60. Coffey C, Carlin JB, Lynskey M, Li N, Patton GC. Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study. Br J Psychiatry. 2003;182:330–6.

    Article  PubMed  Google Scholar 

  61. Von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen HU. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend. 2002;68(1):49–64.

    Article  Google Scholar 

  62. Korf DJ, Benschop A, Wouters M. Differential responses to cannabis potency: a typology of users based on self-reported consumption behaviour. Int J Drug Policy. 2007;18(3):168–76.

    Article  PubMed  Google Scholar 

  63. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA. 2004;291(17):2114–21.

    Article  PubMed  CAS  Google Scholar 

  64. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36(10):1447–60.

    Article  PubMed  Google Scholar 

  65. Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction. 2001;96(5):737–48.

    Article  PubMed  CAS  Google Scholar 

  66. Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction. 2008;103(3):439–49.

    Article  PubMed  Google Scholar 

  67. Boden JM, Fergusson DM, Horwood LJ. Illicit drug use and dependence in a New Zealand birth cohort. Aust NZ J Psychiatry. 2006;40(2):156–63.

    Article  Google Scholar 

  68. Van Laar M, Cruts G, Van Gageldonk A, Croes E, Van Ooyen-Houben M, Meijer R, et al. Drug situation 2006 the Netherlands: report to the EMCDDA. Utrecht: Trimbos Institute; 2007.

    Google Scholar 

  69. Reuter P, Trautmann F. A report on global illicit drugs markets 1998-2007: full report. Brussel: European Communities; 2009.

    Google Scholar 

  70. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Cocaine and crack cocaine: a growing public health issue. Lisbon: EMCDDA; 2007.

    Google Scholar 

  71. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479–88.

    Article  PubMed  Google Scholar 

  72. Chen CY, Anthony JC. Epidemiological estimates of risk in the process of becoming dependent upon cocaine: cocaine hydrochloride powder versus crack cocaine. Psychopharmacology (Berl). 2004;172(1):78–86.

    Article  CAS  Google Scholar 

  73. Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA. 1996;276(19):1580–8.

    Article  PubMed  CAS  Google Scholar 

  74. Hay G, Gannon M, MacDougall J, Millar T, Williams K, Eastwood C, et al. National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2006/07: a summary of key findings: research report 9. London: Home Office; 2008.

    Google Scholar 

  75. McKetin R, McLaren J, Kelly E, Hall W, Hickman M. Estimating the number of regular and dependent methamphetamine users in Australia. Sydney: National Drug and Alcohol Research Centre; 2005.

    Google Scholar 

  76. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2009;107:1–10.

    Article  Google Scholar 

  77. Wu LT, Ringwalt CL, Mannelli P, Patkar AA. Hallucinogen use disorders among adult users of MDMA and other hallucinogens. Am J Addict. 2008;17(5):354–63.

    Article  PubMed  Google Scholar 

  78. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol. 2001;16(8):599–606.

    Article  PubMed  CAS  Google Scholar 

  79. Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009;13(6):3–4.

    Google Scholar 

  80. Peters GJY, Kok G, Schaalma HP. Careers in ecstasy use: do ecstasy users cease of their own accord? Implications for intervention development. BMC Public Health. 2008;8:376.

    Article  PubMed  Google Scholar 

  81. Blanken P, Hendriks VM, Van Ree JM, Van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction. 2010;105(2):300–8.

    Article  PubMed  Google Scholar 

  82. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction. 2010;105(1):29–37.

    Article  PubMed  Google Scholar 

  83. Gilson AM, Kreis PG. The burden of the nonmedical use of ­prescription opioid analgesics. Pain Med. 2009;10 Suppl 2:S89–100.

    Article  PubMed  Google Scholar 

  84. Hay G, Gannon M, MacDougall J, Millar T, Williams K, Eastwood C, et al. National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2006/07: a summary of key findings. London: Home Office; 2008.

    Google Scholar 

  85. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.

    Article  PubMed  Google Scholar 

  86. Wiessing L, Van de Laar MJ, Donoghoe MC, Guarita B. HIV among injecting drug users in Europe: increasing trends in the East. Eurosurveillance. 2008;13(50):11.

    Google Scholar 

  87. Crofts N. Going where the epidemic is. Epidemiology and control of hepatitis C among injecting drug users. Aust Fam Phys. 2001;30(5):420–5.

    CAS  Google Scholar 

  88. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.

    Article  PubMed  Google Scholar 

  89. Brand DA, Saisana M, Rynn LA, Pennoni F, Lowenfels AB. Comparative analysis of alcohol control policies in 30 countries. PLOS Med. 2007;4:752–9.

    Article  Google Scholar 

  90. Rehm J, Taylor B, Room R. Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006;25(6):503–13.

    Article  PubMed  Google Scholar 

  91. Collins DJ, Lapsley HM. The costs of tobacco, alcohol and illicit drug abuse to Australian society in 2004/05: Summary version. Canberra: Commonwealth of Australia; 2008.

    Google Scholar 

  92. WHO. Evidence for the effectiveness and cost-effectiveness of interventions to reduce alcohol-related harm. Kopenhagen: WHO Regional Office for Europe; 2009.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Trimbos Institute, Da Costakade 45, 725, 3500 AS, Utrecht, The Netherlands

    Margriet van Laar

Authors
  1. Margriet van Laar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margriet van Laar .

Editor information

Editors and Affiliations

  1. Inst. Pharmaceutical Sciences, Department of Psychopharmacology, Utrecht University, Universiteitsweg 99, Utrecht, 3584CG, Netherlands

    Joris C. Verster

  2. Dept. Psychiatry, Medical University of South Carolina, President St. 67, Charleston, 29425, South Carolina, USA

    Kathleen Brady

  3. School of Medicine, Div. Alcoholism & Drug Abuse, New York University, First Ave. 550, New York, 10016, New York, USA

    Marc Galanter

  4. Institute of Psychiatry, King's College London, National Addiction Centre, Windsor Walk 4, London, SE5 8AF, United Kingdom

    Patricia Conrod

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

van Laar, M. (2012). Epidemiology of Alcohol and Drug Use. In: Verster, J., Brady, K., Galanter, M., Conrod, P. (eds) Drug Abuse and Addiction in Medical Illness. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3375-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3375-0_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3374-3

  • Online ISBN: 978-1-4614-3375-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation